RayKnowChina Research Map
Shortlist

Nanjing

Zhongda Hospital, Southeast University

东南大学附属中大医院

Listed for 18 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at Zhongda Hospital, Southeast University

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Oesophageal squamous cell carcinoma食管鳞状细胞癌18 papers led
  2. Hepatocellular carcinoma肝细胞癌59 papers led9 open trials led
  3. Stomach cancer胃癌21 papers led1 open trial led
  4. Retinoblastoma视网膜母细胞瘤1 paper led
  5. Chordoma脊索瘤0 papers led
  6. Osteosarcoma骨肉瘤3 papers led
  7. Gastrointestinal stromal tumour胃肠道间质瘤1 paper led
  8. Neuroblastoma神经母细胞瘤2 papers led
  9. Ewing sarcoma尤文肉瘤2 papers led
  10. Multiple myeloma多发性骨髓瘤4 papers led
  11. B-cell acute lymphoblastic leukaemiaB 细胞急性淋巴细胞白血病0 papers led
  12. Thrombotic thrombocytopenic purpura血栓性血小板减少性紫癜1 paper led
  13. Idiopathic pulmonary fibrosis特发性肺纤维化1 paper led
  14. Amyotrophic lateral sclerosis肌萎缩侧索硬化症1 paper led
  15. Fabry disease法布雷病0 papers led
  16. IgA nephropathyIgA 肾病3 papers led
  17. Primary biliary cholangitis原发性胆汁性胆管炎1 paper led
  18. Congenital diaphragmatic hernia先天性膈疝1 paper led

Not listed for: Nasopharyngeal carcinoma, Hepatoblastoma, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Beta thalassaemia, Haemophilia A, Atypical haemolytic uraemic syndrome, Fanconi anaemia, Neuromyelitis optica spectrum disorder, IgG4-related disease, Myasthenia gravis, Moyamoya disease, Wilson disease, Biliary atresia, Anti-NMDA receptor encephalitis, Takayasu arteritis, Hepatic echinococcosis, Lymphangioleiomyomatosis, Spinal muscular atrophy, Pompe disease, Duchenne muscular dystrophy, Behçet disease, Alport syndrome, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Primary sclerosing cholangitis, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Oesophageal squamous cell carcinoma

食管鳞状细胞癌

Led 18 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.6%.

Papers led
18
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 3320212022: 3320222023: 5520232024: 4420242025: 332025

5 hospitals in Nanjing for oesophageal squamous cell carcinoma191 hospitals in China for oesophageal squamous cell carcinoma

No open trial on oesophageal squamous cell carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesEarly detection & endoscopyImaging & AIRadiotherapy
Departments in papersGastroenterology / hepatologyMedical oncologyRadiology / nuclear medicine

Over half of these papers are lab or animal studies.

Papers it led18
  1. Knockdown of WISP1/DKK1 restrains phenotypic plasticity in esophageal squamous cell carcinoma by suppressing epithelial-mesenchymal transition and stemness.2025Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  2. Cervical Incision-Free Technique for R0 Resection in Cervicothoracic Esophageal Carcinoma: A Novel Approach of the Chai's Supra-Thoracic Apex Technique.2025Journal of laparoendoscopic & advanced surgical techniques. Part A
  3. Bioinformatics analysis to identify endocrine-disrupting chemicals targeting key ESCC-related genes.2025Toxicology mechanisms and methods
  4. Synergism of Fusobacterium periodonticum and N-nitrosamines promote the formation of EMT subtypes in ESCC by modulating Wnt3a palmitoylation.2024Gut microbesFree full text
  5. A novel upregulated hsa_circ_0032746 regulates the oncogenesis of esophageal squamous cell carcinoma by regulating miR-4270/MCM3 axis.2024Human genomicsFree full text
  6. The role of JMJD2A in immune evasion and malignant behavior of esophageal squamous cell carcinoma.2024International immunopharmacology
  7. Artificial intelligence enhances the management of esophageal squamous cell carcinoma in the precision oncology era.2024World journal of gastroenterologyFree full text
  8. LINC01116 modulates EMT process via binding with AGO1 mRNA in oesophageal squamous cell carcinoma.2023Biochimica et biophysica acta. Molecular cell research
  9. Artificial intelligence assisted cytological detection for early esophageal squamous epithelial lesions by using low-grade squamous intraepithelial lesion as diagnostic threshold.2023Cancer medicineFree full text
  10. Analysis of white-light imaging-based features predictive for determination of lesion depths of superficial flat esophageal squamous cell carcinoma: a retrospective multicenter study from China.2023European journal of medical researchFree full text
  11. Role of interferon alpha-inducible protein 6 in modulating the proliferation, apoptosis and senescence of oesophageal squamous cell carcinoma cells.2023Journal of physiology and pharmacology : an official journal of the Polish Physiological Society
  12. Insulin-like growth factor-2 mRNA-binding protein 3 promotes cell migration, invasion, and epithelial-mesenchymal transition of esophageal squamous cell carcinoma cells by targeting zinc finger E-box-binding homeobox 1 mRNA.2023Molecular carcinogenesis
  13. SIRT3 Promotes the Development of Esophageal Squamous Cell Carcinoma by Regulating Hexokinase 2 through the AKT Signaling Pathway.2022Bulletin of experimental biology and medicine
  14. LncRNA SNHG16 promotes development of oesophageal squamous cell carcinoma by interacting with EIF4A3 and modulating RhoU mRNA stability.2022Cellular & molecular biology lettersFree full text
  15. A Rapid Cytological Screening as pre-Endoscopy Screening for Early Esophageal Squamous Cell Lesions: A Prospective Pilot Study from a Chinese Academic Center.2022Technology in cancer research & treatmentFree full text
  16. Construction and Validation of an Immune-Related Gene Prognostic Index for Esophageal Squamous Cell Carcinoma.2021BioMed research internationalFree full text
  17. Ultrasound-Stimulated Microbubbles Inhibit Aggressive Phenotypes and Promotes Radiosensitivity of esophageal squamous cell carcinoma.2021BioengineeredFree full text
  18. Biological and clinical implications of metastasis-associated circular RNAs in oesophageal squamous cell carcinoma.2021FEBS open bioFree full text
Chinese-language papers (not in the count)1
  1. [Efficacy and safety of endoscopic submucosal dissection with additional radiotherapy for T1a-MM/T1b-SM esophageal squamous cell carcinoma].2023Zhonghua yi xue za zhi
More papers found outside PubMed (not counted)5
  1. 271O Final analysis and biomarker evaluation of JUPITER-06: A phase III trial of toripalimab plus chemotherapy in advanced or metastatic esophageal squamous cell carcinoma2025Annals of Oncologyarticle
  2. Minimally Invasive Inflatable Mediastinoscope-Assisted Laparoscopic Esophagectomy for Esophageal Cancer: Case Series and Review2025American Journal of Clinical and Experimental Medicinearticle
  3. Surgical Management of Upper Thoracic Esophageal Squamous Cell Carcinoma with Concomitant Hypersplenism: Integration of Chai's Supra-Thoracic Apex Technique with Laparoscopic Splenectomy - A Technical Innovation Case Study with Systematic R2025International Journal of Surgery & Surgical Techniquesreview
  4. 1373MO JUPITER-06: A randomized, double-blind, phase III study of toripalimab versus placebo in combination with first-line chemotherapy for treatment naive advanced or metastatic esophageal squamous cell carcinoma (ESCC)2021Annals of Oncologyarticle
  5. First-line pembrolizumab plus chemotherapy versus chemotherapy in patients with advanced esophageal cancer: Chinese subgroup analysis of KEYNOTE-590.2021Journal of Clinical Oncologyconference-abstract

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatocellular carcinoma

肝细胞癌

Led 59 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.4%.

Papers led
59
2021–2025
Trials led
33
any status, ClinicalTrials.gov
Open trials led
9
recruiting or about to
Open trials as a site
6
led by another institution
Papers led per year
2021: 6620212022: 111120222023: 8820232024: 121220242025: 17172025

7 hospitals in Nanjing for hepatocellular carcinoma192 hospitals in China for hepatocellular carcinoma

Open trials with this hospital 15

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Multicenter Prospective Study on the Performance of Spectral CT for Evaluating Treatment Response After TACE in Hepatocellular Carcinoma
    Phase
    Not given
    Started
    2026-01
    Registry
    NCT07351669

    Age 18 years to 75 years (registered criteria)

    Led by Zhongda Hospital, Southeast UniversityNanjing

  2. Recruiting
    SIRT Versus cTACE for Unresectable HCC (CHANCE2506)
    Phase
    N/A
    Started
    2025-04
    Registry
    NCT06909708

    Age 18 years to Not stated (registered criteria)

    Led by Zhongda Hospital, Southeast UniversityNanjing

  3. Recruiting
    Intravascular Radiofrequency Ablation of Sympathetic Nerves for the Treatment of Hepatocellular Carcinoma
    Phase
    N/A
    Started
    2024-02
    Registry
    NCT06694636

    Age 25 years to 75 years (registered criteria)

    Led by Zhongda Hospital, Southeast UniversityNanjing

  4. Recruiting
    Novel Subtypes and Treatment Strategies of Patients with Unresectable Combined Hepatocellular Cholangiocarcinoma Based on Multimodal Data
    Phase
    Not given
    Started
    2024-12
    Registry
    NCT06849180

    Age 18 years to Not stated (registered criteria)

    Led by Zhongda Hospital, Southeast UniversityNanjing

  5. Recruiting
    DEB-TACE With Visualable Microspheres Versus PVA Microspheres for HCC
    Phase
    N/A
    Started
    2023-12
    Registry
    NCT06190665

    Age 18 years to 80 years (registered criteria)

    Led by Zhongda Hospital, Southeast University; 1 listed hospital as study siteBeijing, Nanjing

  6. Recruiting
    Regional Lymph Node Metastasis and Survival Outcomes in Advanced HCC
    Phase
    Not given
    Started
    2018-06
    Registry
    NCT06876753

    Age 18 years to 80 years (registered criteria)

    Led by Zhongda Hospital, Southeast UniversityNanjing

  7. Not yet recruiting
    Heterogeneity of Treatment Effects of Adding Locoregional Therapies to Atezolizumab Plus Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma (ISMIO-026)
    Phase
    Not given
    Started
    2026-09
    Registry
    NCT07824765

    Age 18 years to Not stated (registered criteria)

    Led by Zhongda Hospital, Southeast UniversityNanjing

  8. Not yet recruiting
    TACE in Combination With Tislelizumab and Lenvatinib for Advanced HCC (CHANCE2602)
    Phase
    Not given
    Started
    2026-09
    Registry
    NCT07836309

    Age 16 years to Not stated (registered criteria)

    Led by Zhongda Hospital, Southeast UniversityNanjing

  9. Not yet recruiting
    EDN Combined With TACE/HAIC and Second-Line Immune-Targeted Treatment Versus TACE/HAIC Alone in Locally Advanced HCC With Portal Vein Tumor Thrombosis After First-Line Therapy Failure: A Prospective, Multicenter, Randomized Controlled Trial
    Phase
    Phase 1/Phase 2
    Started
    2025-09
    Registry
    NCT07187284

    Age 18 years to 75 years (registered criteria)

    Led by Zhongda Hospital, Southeast UniversityNanjing

  10. Recruiting
    A Phase II/III Trial Comparing Transarterial Tirapazamine Embolization (TATE) With cTACE for Intermediate-stage Liver Cancer.
    Phase
    Phase 2/Phase 3
    Started
    2025-03
    Registry
    NCT06844357

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteNanjing

  11. Recruiting
    GKL-006 Injection Plus TACE Versus TACE Alone in Patients With Unresectable Hepatocellular Carcinoma
    Phase
    Phase 2
    Started
    2025-11
    Registry
    NCT07209813

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesBeijing, Changsha, Hangzhou, Nanchang, Nanjing, Zhengzhou

  12. Recruiting
    MDN-001 Injection for the Treatment of Unresectable Primary Hepatocellular Carcinoma.
    Phase
    Phase 1
    Started
    2025-08
    Registry
    NCT07391839

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 8 listed hospitals as study sitesFuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Nanjing, Shanghai, Zhengzhou

  13. Recruiting
    A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma
    Phase
    Phase 3
    Started
    2024-08
    Registry
    NCT06371157

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesChangsha, Hangzhou, Nanjing, Zhengzhou

  14. Not yet recruiting
    A Study of TACE in Combination With SHR-8068, Adebrelimab, and Bevacizumab Versus TACE in Participants With Incurable Hepatocellular Carcinoma
    Phase
    Phase 3
    Started
    2026-11
    Registry
    NCT07691762

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesNanjing, Shanghai

  15. Not yet recruiting
    A Clinical Trial Assessing the Safety and Efficacy of Biodegradable Magnesium Embolic Microspheres for Primary Hepatocellular Carcinoma
    Phase
    Phase 3
    Started
    2025-01
    Registry
    NCT06779461

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBengbu, Guangzhou, Lanzhou, Nanjing, Shanghai, Tianjin, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesLocal treatment (ablation, TACE, HAIC)Recurrence & prognosisImaging, AI & early detection
Departments in papersRadiology / nuclear medicineSurgery (general/hepatobiliary/pancreatic)Medical oncologyRadiation oncology
Papers it led59
  1. The METAL Score for Early Stratification of Radiological Response and Survival in Hepatocellular Carcinoma Treated with TACE and Immunotherapy Combinations.2026Academic radiology
  2. Decoding tumor heterogeneity with imaging biomarkers predicts response to TACE plus immunotherapy and targeted therapy in HCC (CHANCE2204).2026Hepatology (Baltimore, Md.)Free full text
  3. BRIX1 activated by mTORC1-SP1 signaling regulates ribosome biogenesis and alternative splicing to promote hepatocellular carcinoma progression.2026Hepatology international
  4. Inhibition of the U12-type splicing factor ZCRB1 mediates retention of the USP21 minor intron to suppress malignant progression in hepatocellular carcinoma.2026Hepatology international
  5. Identification of a Novel TIM-3 Targeting Peptides Probe to Indicate the Immunomodulation of SBRT Combined with Anti-TIM-3 Therapy in HCC.2026Molecular imaging and biology
  6. LI-RADS Nonradiation Treatment Response Algorithm Version 2024: Diagnostic Performance and Impact of Ancillary Features.2025AJR. American journal of roentgenology
  7. Dynamic changes of radiological and radiomics patterns based on MRI in viable hepatocellular carcinoma after transarterial chemoembolization.2025Abdominal radiology (New York)
  8. The nVR model: prediction of LI-RADS treatment response nonviable recurrence of hepatocellular carcinoma after primary transarterial chemoembolization.2025Abdominal radiology (New York)
  9. Tailored Liposomal Nanomedicine Suppresses Incomplete Radiofrequency Ablation-Induced Tumor Relapse by Reprogramming Antitumor Immunity.2025Advanced healthcare materials
  10. Arginine-Loaded Nano-Calcium-Phosphate-Stabilized Lipiodol Pickering Emulsions Potentiates Transarterial Embolization-Immunotherapy.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  11. Risk Factors and Survival Analysis of Spontaneously Ruptured Hepatocellular Carcinoma: A Retrospective Cohort Study in Bilateral Centers.2025Annals of surgical oncology
  12. Elucidating the role of AC026412.3 in hepatocellular carcinoma: a prognostic disulfidptosis-related LncRNAs model perspective.2025BMC gastroenterologyFree full text
  13. FOXM1 promotes malignant biological behavior and metabolic reprogramming by targeting SPINK1 in hepatocellular carcinoma and affecting the p53 pathway.2025Biochimica et biophysica acta. Molecular basis of disease
  14. Pickering emulsion with tumor vascular destruction and microenvironment modulation for transarterial embolization therapy.2025Biomaterials
  15. Co-delivery of SN38 and MEF2D-siRNA via tLyp-1-modified liposomes reverses PD-L1 expression induced by STING activation in hepatocellular carcinoma.2025Colloids and surfaces. B, Biointerfaces
  16. Radiosensitization strategies for hepatocellular carcinoma: Mechanisms, therapeutic advances, and clinical perspectives.2025Critical reviews in oncology/hematology
  17. Development of a PPP1R14B-associated immune prognostic model for hepatocellular carcinoma.2025European journal of medical researchFree full text
  18. A nationwide investigation on imaging follow-up after Locoregional therapy for hepatocellular carcinoma in China: Current practices and challenges.2025European journal of radiology
  19. Machine learning and multi-omics characterization of SLC2A1 as a prognostic factor in hepatocellular carcinoma: SLC2A1 is a prognostic factor in HCC.2025Gene
  20. DiabetesLiver score: A non-invasive algorithm for advanced liver fibrosis and liver-related outcomes in type 2 diabetes mellitus population.2025Med (New York, N.Y.)
  21. MEG3 rs7158663 genetic polymorphism is associated with the risk of hepatocellular carcinoma.2025Nucleosides, nucleotides & nucleic acids
  22. Combination locoregional and systemic therapies in hepatocellular carcinoma.2025The lancet. Gastroenterology & hepatology
  23. Dual-Synergistic Nanomodulator Alleviates Exosomal PD-L1 Expression Enabling Exhausted Cytotoxic T Lymphocytes Rejuvenation for Potentiated iRFA-Treated Hepatocellular Carcinoma Immunotherapy.2024ACS nano
  24. Diagnostic performance of MRI for residual or recurrent hepatocellular carcinoma after locoregional treatment according to contrast agent type: a systematic review and meta‑analysis.2024Abdominal radiology (New York)
  25. Predicting cachexia in hepatocellular carcinoma patients: a nomogram based on MRI features and body composition.2024Acta radiologica (Stockholm, Sweden : 1987)
  26. Study on the mechanism of liver cancer immune escape mediated by MINDY1 through regulation of PD-L1 ubiquitination level.2024Biomolecules & biomedicineFree full text
  27. Transarterial Chemoembolization with Epirubicin-Loaded Microspheres for Hepatocellular Carcinoma: A Prospective, Single-Arm, Multicenter, Phase 2 Study (STOPPER Trial).2024Cardiovascular and interventional radiologyFree full text
  28. Functional Liver Imaging Score Derived from Gadoxetic Acid-enhanced MRI Predicts Cachexia and Prognosis in Hepatocellular Carcinoma Patients.2024Current medical science
  29. Single-cell landscape identifies the immunophenotypes and microenvironments of HBV-positive and HBV-negative liver cancer.2024Hepatology communicationsFree full text
  30. Longitudinal Body Composition Identifies Hepatocellular Carcinoma With Cachexia Following Combined Immunotherapy and Target Therapy (CHANCE2213).2024Journal of cachexia, sarcopenia and muscleFree full text
  31. MRI-Based Radiomics and Deep Learning in Biological Characteristics and Prognosis of Hepatocellular Carcinoma: Opportunities and Challenges.2024Journal of magnetic resonance imaging : JMRI
  32. TPA: Two-stage progressive attention segmentation framework for hepatocellular carcinoma on multi-modality MRI.2024Medical physics
  33. Prognostic difference between surgery and external radiation in patients with stage I liver cancer based on competitive risk model and conditional survival rate.2024PloS oneFree full text
  34. Locoregional therapies for hepatocellular carcinoma: The current status and future perspectives.2024United European gastroenterology journalFree full text
  35. GBAP1 functions as a tumor promotor in hepatocellular carcinoma via the PI3K/AKT pathway.2023BMC cancerFree full text
  36. LncRNA HClnc1 facilitates hepatocellular carcinoma progression by regulating PKM2 signaling and indicates poor survival outcome after hepatectomy.2023Cancer medicine
  37. Real-world efficacy and safety of TACE plus camrelizumab and apatinib in patients with HCC (CHANCE2211): a propensity score matching study.2023European radiologyFree full text
  38. Letter to the editor: Hepatitis B virus reactivation in immune checkpoint inhibitor-based combination therapies for hepatocellular carcinoma.2023Hepatology (Baltimore, Md.)
  39. Irradiation stent with 125 I plus TACE versus sorafenib plus TACE for hepatocellular carcinoma with major portal vein tumor thrombosis: a multicenter randomized trial.2023International journal of surgery (London, England)RCTFree full text
  40. Hepatocellular Brg1 promotes CCl4-induced liver inflammation, ECM accumulation and fibrosis in mice.2023PloS oneFree full text
  41. Predicting Microvascular Invasion in Hepatocellular Carcinoma Using CT-based Radiomics Model.2023Radiology
  42. Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001).2023Signal transduction and targeted therapyFree full text
  43. ASO Author Reflections: Preoperative Microvascular Invasion Prediction to Assist in Surgical Plan for Single Hepatocellular Carcinoma-A Better Algorithm of Necessity.2022Annals of surgical oncology
  44. Preoperative Microvascular Invasion Prediction to Assist in Surgical Plan for Single Hepatocellular Carcinoma: Better Together with Radiomics.2022Annals of surgical oncology
  45. Exosome-transmitted circ_002136 promotes hepatocellular carcinoma progression by miR-19a-3p/RAB1A pathway.2022BMC cancerFree full text
  46. I-125 seeds brachytherapy with transcatheter arterial chemoembolization for subcapsular hepatocellular carcinoma.2022BMC gastroenterologyFree full text
  47. Postoperative survival analysis of hepatocellular carcinoma patients with liver cirrhosis based on propensity score matching.2022BMC surgeryFree full text
  48. Circular RNA hsa_circ_0032683 inhibits the progression of hepatocellular carcinoma by sponging microRNA-338-5p.2022BioengineeredFree full text
  49. Identification of HLA-A2 restricted epitopes of glypican-3 and induction of CTL responses in HLA-A2 transgenic mice.2022Cancer immunology, immunotherapy : CIIFree full text
  50. TACE with dicycloplatin in patients with unresectable hepatocellular carcinoma: a multicenter randomized phase II trial.2022European radiologyRCT
  51. Combination of TACE and Lenvatinib as a promising option for downstaging to surgery of initially unresectable intrahepatic cholangiocarcinoma.2022Investigational new drugs
  52. Safety and immunogenicity of COVID-19 vaccination in patients with hepatocellular carcinoma (CHESS-NMCID 2101): A multicenter prospective study.2022Journal of medical virologyFree full text
  53. Target and drug predictions for SARS-CoV-2 infection in hepatocellular carcinoma patients.2022PloS oneFree full text
  54. Circular RNA circ_0008274 upregulates granulin to promote the progression of hepatocellular carcinoma via sponging microRNA -140-3p.2021BioengineeredFree full text
  55. I125 irradiation stent for treatment of hepatocellular carcinoma with portal vein thrombosis: A meta-analysis.2021Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique
  56. Portal Vein Irradiation Stent Plus Chemoembolization versus External Radiotherapy Plus Chemoembolization in Hepatocellular Carcinoma with Portal Vein Tumour Thrombus: A Retrospective Study.2021Cardiovascular and interventional radiology
  57. The clinical efficiency of TACE combined with simultaneous computed tomography-guided radiofrequency ablation for advanced hepatocellular carcinoma.2021Investigational new drugs
  58. Comparison of MRI and CT for the Prediction of Microvascular Invasion in Solitary Hepatocellular Carcinoma Based on a Non-Radiomics and Radiomics Method: Which Imaging Modality Is Better?2021Journal of magnetic resonance imaging : JMRI
  59. The Evolving Landscape of Checkpoint Inhibitor Combination Therapy in the Treatment of Advanced Hepatocellular Carcinoma.2021Targeted oncology
Chinese-language papers (not in the count)2
  1. [Research progress of adjuvant TACE therapy for liver cancer after radical resection].2022Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatologyFree full text
  2. [Research progress of prognostic analysis and clinicopathological characteristics of hepatoid adenocarcinoma of the stomach].2021Zhonghua zhong liu za zhi [Chinese journal of oncology]
All its trials on ClinicalTrials.gov, any status47
  1. Heterogeneity of Treatment Effects of Adding Locoregional Therapies to Atezolizumab Plus Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma (ISMIO-026)Not yet recruitingNCT07824765Lead sponsorStart 2026-09
  2. TACE in Combination With Tislelizumab and Lenvatinib for Advanced HCC (CHANCE2602)Not yet recruitingNCT07836309Lead sponsorStart 2026-09
  3. A Multicenter Prospective Study on the Performance of Spectral CT for Evaluating Treatment Response After TACE in Hepatocellular CarcinomaRecruitingNCT07351669Lead sponsorStart 2026-01
  4. SIRT Versus cTACE for Unresectable HCC (CHANCE2506)RecruitingNCT06909708Lead sponsorN/AStart 2025-04
  5. EDN Combined With TACE/HAIC and Second-Line Immune-Targeted Treatment Versus TACE/HAIC Alone in Locally Advanced HCC With Portal Vein Tumor Thrombosis After First-Line Therapy Failure: A Prospective, Multicenter, Randomized Controlled TrialNot yet recruitingNCT07187284Lead sponsorPhase 1/Phase 2Start 2025-09
  6. Intravascular Radiofrequency Ablation of Sympathetic Nerves for the Treatment of Hepatocellular CarcinomaRecruitingNCT06694636Lead sponsorN/AStart 2024-02
  7. Novel Subtypes and Treatment Strategies of Patients with Unresectable Combined Hepatocellular Cholangiocarcinoma Based on Multimodal DataRecruitingNCT06849180Lead sponsorStart 2024-12
  8. DEB-TACE With Visualable Microspheres Versus PVA Microspheres for HCCRecruitingNCT06190665Lead sponsorN/AStart 2023-12
  9. Regional Lymph Node Metastasis and Survival Outcomes in Advanced HCCRecruitingNCT06876753Lead sponsorStart 2018-06
  10. Development and Prospective Validation of a Heterogeneous Treatment Effect-Based Decision Model for Transarterial Chemoembolization Combined With or Without Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular CarcinomaCompletedNCT07109336Lead sponsorN/AStart 2025-08
  11. Prognosis Stratification for Advanced HCC Receiving TACE with PD-1/PD-L1 Inhibitors and Molecular Target TherapiesStatus unknownNCT06607120Lead sponsorStart 2024-06
  12. TACE Combined With ICIs Plus MTT After 125I Irradiation Stent Placement in HCC With Main PVTT.Status unknownNCT06669377Lead sponsorStart 2024-01
  13. TACE With Thermosensitive Nanogel Versus Embosphere for HCCStatus unknownNCT06593964Lead sponsorN/AStart 2024-09
  14. WISH for Treatment Selection and Survival Prediction in Unresectable Hepatocellular CarcinomaCompletedNCT07065786Lead sponsorStart 2024-01
  15. Impact of Clinical Evident Portal Hypertension on HCC With TACE (CHANCE-CHESS 2301)Status unknownNCT05703750Lead sponsorStart 2023-05
  16. Yttrium-90 Carbon Microspheres in Patients With Unresectable Hepatocellular CarcinomaStatus unknownNCT05957640Lead sponsorPhase 1Start 2023-05
  17. CT-based HVPG Assessment for Predicting the Prognosis of HCC With TACE (CHANCE-CHESS 2302)Status unknownNCT05704192Lead sponsorStart 2023-05
  18. TACE Combined With Penpulimab and Anlotinib for Advanced HCCStatus unknownNCT05344924Lead sponsorPhase 2/Phase 3Start 2022-10
  19. Lipiodol-TACE With Idarubicin for Hepatocellular CarcinomaStatus unknownNCT05280444Lead sponsorPhase 2/Phase 3Start 2022-05
  20. TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Advanced HCCCompletedNCT05332821Lead sponsorStart 2022-12
  21. Assessing the Prognosis of TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for HCC by Using Clinical and Imaging BiomarkersStatus unknownNCT05278195Lead sponsorStart 2022-04
  22. TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Intermediate HCCCompletedNCT05332496Lead sponsorStart 2022-12
  23. Lipiodol-TACE With Idarubicin Based On a Specific Emulsion Ratio for Hepatocellular CarcinomaStatus unknownNCT05631613Lead sponsorStart 2022-12
  24. Efficacy and Safety of TACE in Combination With ICIs for HCC: a Real-world StudyCompletedNCT04975932Lead sponsorStart 2021-07
  25. Tislelizumab in Combination With TACE in Advanced Hepatocellular CarcinomaStatus unknownNCT04652492Lead sponsorPhase 2Start 2020-10
  26. TACE Combined With Camrelizumab and Apatinib in Intermediate and Advanced Hepatocelluar CarcinomaStatus unknownNCT04559607Lead sponsorN/AStart 2020-09
  27. Atezolizumab Plus Bevacizumab Combined With Locoregional Therapies in Unresectable Hepatocellular Carcinoma (ISMIO-001)Active, not recruitingNCT07204327Lead sponsorStart 2020-10
  28. Immune Checkpoint Inhibitors and Anti-vascular Endothelial Growth Factor Antibody/Tyrosine Kinase Inhibitors With or Without TACE for Advanced HCC With Vascular InvasionsCompletedNCT06881446Lead sponsorStart 2018-06
  29. Immune Checkpoint Inhibitors and Anti-vascular Endothelial Growth Factor Antibody/Tyrosine Kinase Inhibitors With or Without HAIC for Unresectable HCC With Portal Vein Tumor ThrombosisCompletedNCT06881433Lead sponsorStart 2018-06
  30. Irradiation Stent Placement Plus TACE for HCC and PVTTStatus unknownNCT03730675Lead sponsorN/AStart 2018-11
  31. ISP-TACE Versus TACE for HCC With PVTTCompletedNCT03108248Lead sponsorStart 2011-01
  32. TACE With Dicycloplatin(TP21) in Unresectable HCCStatus unknownNCT05472896Lead (inferred)Phase 3Start 2022-06
  33. Comparison of Liver and Renal Function After Transarterial Chemoembolization for Primary Hepatocellular Carcinoma With Iso-osmolar Contrast Media and Low Osmolar Contrast MediaStatus unknownNCT01563484Lead (inferred)Start 2012-03
  34. A Study of TACE in Combination With SHR-8068, Adebrelimab, and Bevacizumab Versus TACE in Participants With Incurable Hepatocellular CarcinomaNot yet recruitingNCT07691762Study sitePhase 3Start 2026-11
  35. GKL-006 Injection Plus TACE Versus TACE Alone in Patients With Unresectable Hepatocellular CarcinomaRecruitingNCT07209813Study sitePhase 2Start 2025-11
  36. A Phase II/III Trial Comparing Transarterial Tirapazamine Embolization (TATE) With cTACE for Intermediate-stage Liver Cancer.RecruitingNCT06844357Study sitePhase 2/Phase 3Start 2025-03
  37. MDN-001 Injection for the Treatment of Unresectable Primary Hepatocellular Carcinoma.RecruitingNCT07391839Study sitePhase 1Start 2025-08
  38. A Clinical Trial Assessing the Safety and Efficacy of Biodegradable Magnesium Embolic Microspheres for Primary Hepatocellular CarcinomaNot yet recruitingNCT06779461Study sitePhase 3Start 2025-01
  39. A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular CarcinomaRecruitingNCT06371157Study sitePhase 3Start 2024-08
  40. Chinese HCC Efficacy Evaluation, Response and Safety Study of TareSphereActive, not recruitingNCT06900543Study sitePhase 3Start 2025-04
  41. Safety and Efficacy of TareSphere in Patients With Unresectable Hepatocellular CarcinomaCompletedNCT06310590Study sitePhase 1Start 2023-08
  42. MANDARIN (S6371)CompletedNCT05016245Study sitePhase 3Start 2021-09
  43. To Evaluate the Safety and Efficacy of Microwave Ablation Therapy in Patients With Primary Liver CancerTerminatedNCT04520906Study siteN/AStart 2020-12
  44. A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or AblationCompletedNCT04102098Study sitePhase 3Start 2019-12
  45. STOPPER CHINA:With Tandem Microspheres in the Treatment of Localized Hepatocellular CarcinomaCompletedNCT03113955Study siteN/AStart 2017-10
  46. Safety and Efficacy of Arsenic Trioxide Contained in TACE in the Treatment of HCCStatus unknownNCT02018757Study sitePhase 2Start 2014-01
  47. Synergistic Treatment for Hepatocellular Carcinoma (HCC) Using TACE With AntiangiogenesisStatus unknownNCT00518557Study siteN/AStart 2007-04

Run the PubMed searchClinicalTrials.gov

Cancer

Stomach cancer

胃癌

Led 21 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.2%.

Papers led
21
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 2220212022: 2220222023: 4420232024: 3320242025: 10102025

8 hospitals in Nanjing for stomach cancer218 hospitals in China for stomach cancer

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    The Correlation Between Blood Concentration of Sintilimab and Efficacy and Adverse Reactions in Patients with Advanced Gastric Cancer
    Phase
    Not given
    Started
    2023-02
    Registry
    NCT06702683

    Age 18 years to Not stated (registered criteria)

    Led by Zhongda Hospital, Southeast UniversityNanjing

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesEarly detection & endoscopyImmunotherapy & targeted drugsPeritoneal spread & advanced disease
Departments in papersGastroenterology / hepatologyMedical oncologyPathology / laboratory medicineSurgery (general/hepatobiliary/pancreatic)
Papers it led21
  1. Heterogeneity of T cells regulates tumor immunity mediated by Helicobacter pylori infection in gastric cancer.2025BMC cancerFree full text
  2. Epidemiology of Helicobacter pylori, gastric precancerous lesions and gastric cancer: a multicenter, population-based cross-sectional study in Nanjing.2025BMC infectious diseasesFree full text
  3. Association between weight loss and survival outcomes in patients with gastric cancer: a meta-analysis.2025European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)
  4. Efficacy of human-derived fibrin sealant in preventing postoperative adverse events after gastric endoscopic submucosal dissection: a retrospective multicenter study.2025European journal of medical researchFree full text
  5. Tumor-associated macrophage-derived exosome miR-194 confers cisplatin resistance in GC cells.2025European journal of medical researchFree full text
  6. LncRNA BASP1-AS1 drives PCBP2 K115 lactylation to suppress ferroptosis and confer oxaliplatin resistance in gastric cancer.2025Free radical biology & medicine
  7. Clinical characteristics and prognostic factors of differentiated and undifferentiated early gastric cancer: A retrospective cohort study.2025MedicineFree full text
  8. Safety and efficacy of endoscopic resection for gastric gastrointestinal stromal tumors: a retrospective cohort study.2025Minimally invasive therapy & allied technologies : MITAT : official journal of the Society for Minimally Invasive Therapy
  9. Unraveling the prognostic significance and molecular mechanisms of HKDC1 in cancer via integrated multi-omics and experimental validation.2025Pathology, research and practice
  10. Effects of polyunsaturated fatty acids on gastric cancer immunity and immunotherapy.2025Scientific reportsFree full text
  11. Serum prealbumin level as a biomarker of survival outcomes in patients with gastric cancer: a meta-analysis.2024Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals
  12. Comprehensive evaluation of serum circHAS2 as a novel diagnostic and prognostic biomarker for gastric cancer.2024Molecular carcinogenesis
  13. Clinical value of serum polyunsaturated fatty acids in patients with gastric polyps.2024PeerJFree full text
  14. A Novel Prognostic Biomarker CCR8 for Gastric Cancer and Anti-CCR8 Blockade Attenuate the Immunosuppressive Capacity of Tregs In Vitro.2023Cancer biotherapy & radiopharmaceuticals
  15. Comprehensive Analysis Based on the Cancer Immunotherapy and Immune Activation of Gastric Cancer Patients.2023Genetics researchFree full text
  16. RHOJ Induces Epithelial-to-Mesenchymal Transition by IL-6/STAT3 to Promote Invasion and Metastasis in Gastric Cancer.2023International journal of biological sciencesFree full text
  17. Clinical application and detection techniques of liquid biopsy in gastric cancer.2023Molecular cancerFree full text
  18. Molecular Characteristics, Clinical Significance, and Cancer Immune Interactions of Angiogenesis-Associated Genes in Gastric Cancer.2022Frontiers in immunologyFree full text
  19. From part to whole, operative link on to endoscopic grading of gastric intestinal metaplasia, pathology to endoscopy: gastric intestinal metaplasia graded by endoscopy.2022Future oncology (London, England)
  20. A novel irradiation stent versus conventional irradiation stent for malignant dysphagia: A prospective randomized controlled trial.2021Journal of cancer research and therapeuticsRCT
  21. lncRNA NEAT1 regulates gastric carcinoma cell proliferation, invasion and apoptosis via the miR‑500a‑3p/XBP‑1 axis.2021Molecular medicine reportsFree full text
Chinese-language papers (not in the count)5
  1. [Applications and advances of artificial intelligence in gastric mucosal biopsy pathology].2025Zhonghua bing li xue za zhi = Chinese journal of pathology
  2. [Research on the evaluation of the efficacy of immunotherapy for gastric cancer by tertiary lymphoid structures].2025Zhonghua zhong liu za zhi [Chinese journal of oncology]
  3. [Efficacy of curative endoscopic submucosal dissection for patients with early cardia and non-cardia gastric cancer].2024Zhonghua yi xue za zhi
  4. [Efficacy of alternate mucosa-submucosa clip closure in preventing postoperative complications for patients with gastric mucosal lesions after endoscopic submucosal dissection].2024Zhonghua yi xue za zhi
  5. [Research progress of prognostic analysis and clinicopathological characteristics of hepatoid adenocarcinoma of the stomach].2021Zhonghua zhong liu za zhi [Chinese journal of oncology]
All its trials on ClinicalTrials.gov, any status4
  1. The Correlation Between Blood Concentration of Sintilimab and Efficacy and Adverse Reactions in Patients with Advanced Gastric CancerRecruitingNCT06702683Lead (inferred)Start 2023-02
  2. Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.TerminatedNCT05111626Study sitePhase 3Start 2022-03
  3. HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric CancerStatus unknownNCT04486651Study sitePhase 3Start 2020-09
  4. Enhanced Recovery After Surgery Program for Gastric Cancer: a Multi-center StudyStatus unknownNCT03121729Study siteN/AStart 2017-06

Run the PubMed searchClinicalTrials.gov

Cancer

Retinoblastoma

视网膜母细胞瘤

Led 1 of the 301 English-language PubMed papers on retinoblastoma with an author in mainland China, 2021–2025: 0.3%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

4 hospitals in Nanjing for retinoblastoma196 hospitals in China for retinoblastoma

No open trial on retinoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersOphthalmology / neuro-ophthalmology

Run the PubMed searchClinicalTrials.gov

Cancer

Chordoma

脊索瘤

Led no English-language PubMed papers on chordoma in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

4 hospitals in Nanjing for chordoma88 hospitals in China for chordoma

No open trial on chordoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)1
  1. Survival analysis of patients with spinal chordomas.2019Neurosurgical review

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 3 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.1%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 222025

25 hospitals in Nanjing for osteosarcoma742 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Cancer

Gastrointestinal stromal tumour

胃肠道间质瘤

Led 1 of the 523 English-language PubMed papers on gastrointestinal stromal tumour with an author in mainland China, 2021–2025: 0.2%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

11 hospitals in Nanjing for gastrointestinal stromal tumour261 hospitals in China for gastrointestinal stromal tumour

No open trial on gastrointestinal stromal tumour lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersGastroenterology / hepatology
Papers it led1
  1. Safety and efficacy of endoscopic resection for gastric gastrointestinal stromal tumors: a retrospective cohort study.2025Minimally invasive therapy & allied technologies : MITAT : official journal of the Society for Minimally Invasive Therapy

Run the PubMed searchClinicalTrials.gov

Cancer

Neuroblastoma

神经母细胞瘤

Led 2 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.2%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 0020232024: 0020242025: 002025

10 hospitals in Nanjing for neuroblastoma352 hospitals in China for neuroblastoma

No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurology

Run the PubMed searchClinicalTrials.gov

Cancer

Ewing sarcoma

尤文肉瘤

Led 2 of the 163 English-language PubMed papers on Ewing sarcoma with an author in mainland China, 2021–2025: 1.2%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 112025

3 hospitals in Nanjing for Ewing sarcoma139 hospitals in China for Ewing sarcoma

No open trial on Ewing sarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Blood disorders

Multiple myeloma

多发性骨髓瘤

Led 4 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 0.2%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
3
led by another institution
Papers led per year
2021: 2220212022: 0020222023: 1120232024: 0020242025: 112025

7 hospitals in Nanjing for multiple myeloma178 hospitals in China for multiple myeloma

Open trials with this hospital 3

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
    Phase
    Phase 1
    Started
    2026-05
    Registry
    NCT07477587

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 46 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Ningbo, Qingdao, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Weifang, Wenzhou, Wuhan, Wuxi, Xiamen, Xuzhou, Zhengzhou

  2. Recruiting
    A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
    Phase
    Phase 3
    Started
    2022-10
    Registry
    NCT05552222

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 29 listed hospitals as study sitesBeijing, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Jinan, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shenzhen, Tianjin, Wenzhou, Wuhan, Xi'an, Xiamen, Zhengzhou

  3. Not yet recruiting
    Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma
    Phase
    Phase 3
    Started
    2026-06
    Registry
    NCT07569757

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 38 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengde, Chengdu, Chongqing, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Luzhou, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Xi'an, Xuzhou, Zhanjiang, Zhengzhou, Zhuzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesDiagnosis, MRD & risk
Departments in papersMedical oncologyNephrology
Papers it led4
  1. Nephrotic syndrome in a 51-year-old woman with light chain deposition disease.2025Ultrastructural pathology
  2. Clinical and cytogenetic characteristics of primary and secondary plasma cell leukemia under the new IMWG definition criteria: a retrospective study.2023Hematology (Amsterdam, Netherlands)
  3. Identification of hub genes with prognostic values in multiple myeloma by bioinformatics analysis.2021Hematology (Amsterdam, Netherlands)
  4. New insights into genetic characteristics between multiple myeloma and COVID-19: An integrative bioinformatics analysis of gene expression omnibus microarray and the cancer genome atlas data.2021International journal of laboratory hematologyFree full text
All its trials on ClinicalTrials.gov, any status8
  1. Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple MyelomaNot yet recruitingNCT07569757Study sitePhase 3Start 2026-06
  2. A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple MyelomaRecruitingNCT07477587Study sitePhase 1Start 2026-05
  3. A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple MyelomaRecruitingNCT05552222Study sitePhase 3Start 2022-10
  4. Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT06158841Study sitePhase 3Start 2024-05
  5. A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT05083169Study sitePhase 3Start 2021-10
  6. A Study of Subcutaneous Delivery of JNJ-54767414 in Chinese Participants With Multiple MyelomaCompletedNCT04121260Study sitePhase 1Start 2019-12
  7. A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)CompletedNCT03217812Study sitePhase 3Start 2017-11
  8. A Study to Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Participants With Relapsed or Refractory Multiple MyelomaCompletedNCT03234972Study sitePhase 3Start 2017-11

Run the PubMed searchClinicalTrials.gov

Blood disorders

B-cell acute lymphoblastic leukaemia

B 细胞急性淋巴细胞白血病

Led no English-language PubMed papers on B-cell acute lymphoblastic leukaemia in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

3 hospitals in Nanjing for B-cell acute lymphoblastic leukaemia90 hospitals in China for B-cell acute lymphoblastic leukaemia

No open trial on B-cell acute lymphoblastic leukaemia lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
  1. Study of Efficacy and Safety of Flumatinib Combined With Chemotherapy in Ph Positive ALLStatus unknownNCT04375683Lead sponsorPhase 3Start 2020-03

Run the PubMed searchClinicalTrials.gov

Blood disorders

Thrombotic thrombocytopenic purpura

血栓性血小板减少性紫癜

Led 1 of the 64 English-language PubMed papers on thrombotic thrombocytopenic purpura with an author in mainland China, 2021–2025: 1.6%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

3 hospitals in Nanjing for thrombotic thrombocytopenic purpura59 hospitals in China for thrombotic thrombocytopenic purpura

No open trial on thrombotic thrombocytopenic purpura lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Papers it led1
  1. Sudden coma at the onset of severe refractory thrombotic thrombocytopenic purpura with successful treatment.2021Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis

Run the PubMed searchClinicalTrials.gov

Other diseases

Idiopathic pulmonary fibrosis

特发性肺纤维化

Led 1 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 0.1%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

15 hospitals in Nanjing for idiopathic pulmonary fibrosis333 hospitals in China for idiopathic pulmonary fibrosis

No open trial on idiopathic pulmonary fibrosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNephrology

Run the PubMed searchClinicalTrials.gov

Other diseases

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症

Led 1 of the 779 English-language PubMed papers on amyotrophic lateral sclerosis with an author in mainland China, 2021–2025: 0.1%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

8 hospitals in Nanjing for amyotrophic lateral sclerosis194 hospitals in China for amyotrophic lateral sclerosis

No open trial on amyotrophic lateral sclerosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurology

Run the PubMed searchClinicalTrials.gov

Other diseases

Fabry disease

法布雷病

Led no English-language PubMed papers on Fabry disease in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

5 hospitals in Nanjing for Fabry disease85 hospitals in China for Fabry disease

No open trial on Fabry disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNephrology
Chinese-language papers (not in the count)2
  1. [Characteristics of cardiac lesions in 17 patients with Fabry disease].2025Zhonghua xin xue guan bing za zhi
  2. [Analysis of a family with Fabry disease with 15 patients].2024Zhonghua nei ke za zhi

Run the PubMed searchClinicalTrials.gov

Other diseases

IgA nephropathy

IgA 肾病

Led 3 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 0.4%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 112025

8 hospitals in Nanjing for IgA nephropathy346 hospitals in China for IgA nephropathy

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy
    Phase
    Phase 3
    Started
    2025-07
    Registry
    NCT06963827

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 20 listed hospitals as study sitesBaotou, Beijing, Changsha, Chengdu, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing, Nantong, Ningbo, Shanghai, Shenzhen, Wuxi, Xiamen, Zhuhai

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersNephrology

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary biliary cholangitis

原发性胆汁性胆管炎

Led 1 of the 300 English-language PubMed papers on primary biliary cholangitis with an author in mainland China, 2021–2025: 0.3%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

10 hospitals in Nanjing for primary biliary cholangitis173 hospitals in China for primary biliary cholangitis

No open trial on primary biliary cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPathology / laboratory medicine

Run the PubMed searchClinicalTrials.gov

Other diseases

Congenital diaphragmatic hernia

先天性膈疝

Led 1 of the 60 English-language PubMed papers on congenital diaphragmatic hernia with an author in mainland China, 2021–2025: 1.7%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

1 hospital in Nanjing for congenital diaphragmatic hernia46 hospitals in China for congenital diaphragmatic hernia

No open trial on congenital diaphragmatic hernia lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersSurgery (general/hepatobiliary/pancreatic)

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

东南大学附属中大医院

Zhongda Hospital, Southeast University

南京

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR Wikidata
Zhongda Hospital; Zhongda Hospital Southeast University; Zhongda Hospital Affiliated to Southeast University; Zhongda Hospital Lishui Branch; Affiliated Zhongda Hospital of Southeast University; Zhongda Hospital of Southeast University; Nanjing Lishui People's Hospital (Zhongda Hospital Lishui Branch; Southeast University Affiliated Zhongda Hospital

Suggest a correctionDownload the data